Legal Representation
Attorney
Tiffany D. Gehrke
USPTO Deadlines
Next Deadline
13 days remaining
Final Refusal E-Mailed
Due Date
January 09, 2026
Extension Available
Until April 09, 2026
Application History
45 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 9, 2025 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Oct 9, 2025 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Oct 9, 2025 | CNFR | W | SU - FINAL REFUSAL - WRITTEN | Loading... |
| Sep 16, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Sep 16, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Sep 10, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jun 12, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jun 12, 2025 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Jun 12, 2025 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN | Loading... |
| May 15, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| May 15, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| May 15, 2025 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Apr 30, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Feb 3, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Feb 3, 2025 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Feb 3, 2025 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN | Loading... |
| Jan 13, 2025 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Oct 28, 2024 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Jan 11, 2025 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Oct 28, 2024 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Jun 18, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Apr 23, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Apr 23, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Apr 3, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Mar 16, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Feb 27, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Feb 27, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Feb 27, 2024 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| Dec 18, 2023 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| Dec 18, 2023 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Oct 2, 2023 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Oct 2, 2023 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Oct 2, 2023 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Aug 11, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 10, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 10, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 3, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| May 11, 2023 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| May 11, 2023 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Feb 14, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Feb 14, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Feb 14, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Feb 7, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jun 30, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jun 20, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Cells for medical or clinical use in the field of in vivo gene editing therapy for the treatment of cardiovascular diseases; pharmaceutical and biopharmaceutical agents for the treatment of cardiovascular disease in the field of in vivo gene editing therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cardiovascular disease in the field of in vivo gene editing therapy
First Use Anywhere:
Mar 5, 2024
First Use in Commerce:
Mar 5, 2024
Class 042
Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy
First Use Anywhere:
Mar 5, 2024
First Use in Commerce:
Mar 5, 2024
Additional Information
Pseudo Mark
CTX THREE TWO ZERO; CTX THREE HUNDRED TWENTY
Classification
International Classes
005
042